Overview
Paradox Biosciences develops next-generation small-molecule therapeutics targeting synaptic plasticity pathways for the treatment of treatment-resistant depression and PTSD.
More in Neuropharmaceuticals
Latest industry news
Neuralink Connects to Grok AI Agent, Enabling ALS Patient to Control AI and Make Calls by Thought Alone
2026-10-30 · Product
Implanted BCIs Still Lack a Shared Safety Rulebook, and the Field Is Running Out of Time to Write One
2026-10-29 · Research
NeuroXess Raises 700 Million Yuan in Series B to Push 'Three-Comprehensive' BCI Into Clinical Trials
2026-10-28 · Funding
BCI Stimulation Shows Stronger Recovery Signal After Stroke, Landmark Review Finds
2026-10-27 · Research
Company details
Category
💊 Neuropharmaceuticals
Location
San Diego, CA
Funding
Series A — $42M
Website
paradoxbiosciences.comListed
2026-08-31
Is this your company?
Claim this listing to add your logo, full description, team, and products. Premium listings get featured placement.
Claim & upgrade listingAdvertise
Reach neurotech professionals
Newsletter sponsorships, featured listings, and sponsored articles.
View packages →